Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antiemetics | 73 | 2023 | 98 | 20.680 |
Why?
|
Nausea | 84 | 2023 | 176 | 20.410 |
Why?
|
Vomiting | 84 | 2023 | 193 | 19.880 |
Why?
|
Antineoplastic Agents | 54 | 2023 | 2405 | 7.230 |
Why?
|
Neurokinin-1 Receptor Antagonists | 22 | 2019 | 35 | 5.550 |
Why?
|
Quinuclidines | 17 | 2023 | 26 | 3.740 |
Why?
|
Isoquinolines | 15 | 2023 | 73 | 3.420 |
Why?
|
Benzodiazepines | 15 | 2022 | 65 | 3.240 |
Why?
|
Serotonin 5-HT3 Receptor Antagonists | 15 | 2019 | 18 | 3.200 |
Why?
|
Neoplasms | 36 | 2023 | 3003 | 3.140 |
Why?
|
Spiro Compounds | 8 | 2019 | 25 | 2.840 |
Why?
|
Morpholines | 14 | 2018 | 69 | 2.420 |
Why?
|
Serotonin Antagonists | 10 | 2013 | 35 | 1.850 |
Why?
|
Cisplatin | 20 | 2023 | 616 | 1.660 |
Why?
|
Dexamethasone | 21 | 2023 | 344 | 1.550 |
Why?
|
Polysorbates | 2 | 2018 | 3 | 1.300 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 5 | 2018 | 201 | 1.180 |
Why?
|
Humans | 117 | 2023 | 88482 | 1.110 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 2535 | 1.070 |
Why?
|
Ondansetron | 13 | 2019 | 21 | 0.870 |
Why?
|
Double-Blind Method | 22 | 2023 | 1712 | 0.860 |
Why?
|
Pyridines | 4 | 2021 | 316 | 0.840 |
Why?
|
Drug Therapy, Combination | 15 | 2019 | 798 | 0.790 |
Why?
|
Clinical Trials, Phase III as Topic | 8 | 2021 | 172 | 0.790 |
Why?
|
Metoclopramide | 5 | 2013 | 16 | 0.750 |
Why?
|
Receptors, Neurokinin-1 | 6 | 2023 | 14 | 0.750 |
Why?
|
Quality of Life | 13 | 2019 | 1647 | 0.720 |
Why?
|
Clinical Trials as Topic | 11 | 2018 | 1142 | 0.710 |
Why?
|
Fluid Therapy | 1 | 2020 | 51 | 0.710 |
Why?
|
Aged, 80 and over | 25 | 2019 | 6713 | 0.700 |
Why?
|
Aged | 41 | 2021 | 18904 | 0.670 |
Why?
|
Middle Aged | 49 | 2021 | 25649 | 0.660 |
Why?
|
Disease Susceptibility | 1 | 2020 | 199 | 0.660 |
Why?
|
Hospice Care | 3 | 2005 | 40 | 0.660 |
Why?
|
Guideline Adherence | 1 | 2020 | 226 | 0.630 |
Why?
|
Cyclophosphamide | 11 | 2023 | 300 | 0.630 |
Why?
|
Female | 57 | 2023 | 45687 | 0.580 |
Why?
|
Adult | 41 | 2021 | 26303 | 0.560 |
Why?
|
Male | 54 | 2023 | 41953 | 0.530 |
Why?
|
Neurotransmitter Agents | 2 | 2006 | 107 | 0.480 |
Why?
|
Clinical Trials, Phase II as Topic | 5 | 2021 | 175 | 0.480 |
Why?
|
Granisetron | 7 | 2016 | 8 | 0.470 |
Why?
|
Antifungal Agents | 2 | 2005 | 119 | 0.450 |
Why?
|
Piperazines | 3 | 2009 | 280 | 0.400 |
Why?
|
Receptors, Serotonin, 5-HT3 | 4 | 2015 | 15 | 0.390 |
Why?
|
Induction Chemotherapy | 5 | 2018 | 149 | 0.380 |
Why?
|
Piperidines | 2 | 2009 | 163 | 0.360 |
Why?
|
Chemoradiotherapy | 1 | 2013 | 308 | 0.360 |
Why?
|
Drug Combinations | 3 | 2023 | 203 | 0.360 |
Why?
|
Anorexia | 2 | 2009 | 30 | 0.360 |
Why?
|
Appetite Stimulants | 1 | 2009 | 1 | 0.350 |
Why?
|
Megestrol Acetate | 1 | 2009 | 10 | 0.350 |
Why?
|
Drug Administration Schedule | 7 | 2021 | 902 | 0.340 |
Why?
|
Bone Marrow Transplantation | 5 | 1999 | 283 | 0.340 |
Why?
|
Breast Neoplasms | 7 | 2023 | 2976 | 0.340 |
Why?
|
Anti-Bacterial Agents | 3 | 2005 | 777 | 0.330 |
Why?
|
Administration, Oral | 8 | 2021 | 684 | 0.320 |
Why?
|
Antipsychotic Agents | 3 | 2017 | 129 | 0.320 |
Why?
|
Anthracyclines | 7 | 2023 | 38 | 0.310 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2007 | 19 | 0.310 |
Why?
|
Disease Management | 2 | 2020 | 328 | 0.300 |
Why?
|
Clinical Decision-Making | 2 | 2020 | 274 | 0.300 |
Why?
|
Fluoxetine | 1 | 2007 | 42 | 0.300 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2016 | 1944 | 0.300 |
Why?
|
Retrospective Studies | 4 | 2023 | 8869 | 0.290 |
Why?
|
Prospective Studies | 7 | 2023 | 4268 | 0.290 |
Why?
|
Radiotherapy | 2 | 2020 | 331 | 0.290 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2021 | 837 | 0.280 |
Why?
|
Practice Guidelines as Topic | 6 | 2017 | 1038 | 0.270 |
Why?
|
Animals | 20 | 2019 | 27203 | 0.250 |
Why?
|
Mycoses | 1 | 2005 | 46 | 0.250 |
Why?
|
Patient Satisfaction | 4 | 2003 | 460 | 0.250 |
Why?
|
Infusions, Intravenous | 6 | 2019 | 430 | 0.240 |
Why?
|
Treatment Outcome | 7 | 2023 | 8151 | 0.240 |
Why?
|
Neoplasm Staging | 4 | 2020 | 1982 | 0.240 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2019 | 110 | 0.240 |
Why?
|
Bacterial Infections | 1 | 2005 | 184 | 0.230 |
Why?
|
Depression | 1 | 2007 | 499 | 0.230 |
Why?
|
Doxorubicin | 5 | 2013 | 298 | 0.230 |
Why?
|
Injections, Intravenous | 5 | 2019 | 241 | 0.220 |
Why?
|
Cardiovascular System | 1 | 2003 | 62 | 0.220 |
Why?
|
Quinolizines | 5 | 2003 | 6 | 0.210 |
Why?
|
Education, Premedical | 1 | 2001 | 1 | 0.200 |
Why?
|
International Educational Exchange | 1 | 2001 | 6 | 0.200 |
Why?
|
Electrocardiography | 2 | 2003 | 495 | 0.200 |
Why?
|
Indoles | 6 | 2013 | 309 | 0.200 |
Why?
|
Administration, Intravenous | 2 | 2018 | 51 | 0.200 |
Why?
|
Gastrointestinal Agents | 1 | 2023 | 166 | 0.200 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 155 | 0.190 |
Why?
|
Terminally Ill | 1 | 2000 | 23 | 0.190 |
Why?
|
Pilot Projects | 2 | 2020 | 865 | 0.180 |
Why?
|
Complementary Therapies | 1 | 2020 | 56 | 0.170 |
Why?
|
Acetals | 1 | 1999 | 3 | 0.170 |
Why?
|
Prisoners | 1 | 1999 | 44 | 0.170 |
Why?
|
United States | 7 | 2020 | 6877 | 0.170 |
Why?
|
Area Under Curve | 1 | 2019 | 333 | 0.170 |
Why?
|
Half-Life | 2 | 2017 | 96 | 0.160 |
Why?
|
Carboplatin | 1 | 2019 | 304 | 0.160 |
Why?
|
Palliative Care | 1 | 2000 | 264 | 0.160 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 173 | 0.160 |
Why?
|
Delivery of Health Care | 1 | 2023 | 432 | 0.160 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 453 | 0.160 |
Why?
|
Point-of-Care Systems | 1 | 2019 | 144 | 0.150 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2019 | 112 | 0.150 |
Why?
|
Thalidomide | 1 | 2017 | 57 | 0.150 |
Why?
|
Risk Factors | 4 | 2010 | 5439 | 0.150 |
Why?
|
Medicare | 1 | 2020 | 420 | 0.150 |
Why?
|
Adenocarcinoma | 3 | 2019 | 1184 | 0.140 |
Why?
|
Intention to Treat Analysis | 1 | 2016 | 69 | 0.140 |
Why?
|
Attitude of Health Personnel | 1 | 2001 | 642 | 0.140 |
Why?
|
Quality of Health Care | 1 | 2019 | 384 | 0.140 |
Why?
|
Image Enhancement | 1 | 2019 | 567 | 0.130 |
Why?
|
Serotonin | 3 | 2023 | 221 | 0.120 |
Why?
|
Intestinal Neoplasms | 2 | 2005 | 57 | 0.120 |
Why?
|
Molecular Structure | 1 | 2014 | 289 | 0.120 |
Why?
|
Contrast Media | 1 | 2019 | 1087 | 0.110 |
Why?
|
Consensus | 3 | 2023 | 352 | 0.110 |
Why?
|
Cross-Linking Reagents | 1 | 2013 | 86 | 0.110 |
Why?
|
Pancreatic Neoplasms | 1 | 2019 | 659 | 0.110 |
Why?
|
Nucleotides | 1 | 2013 | 97 | 0.110 |
Why?
|
Aromatase Inhibitors | 2 | 1996 | 29 | 0.110 |
Why?
|
Conserved Sequence | 1 | 2013 | 211 | 0.110 |
Why?
|
Appetite | 3 | 2009 | 26 | 0.110 |
Why?
|
Ultraviolet Rays | 1 | 2013 | 193 | 0.100 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2019 | 116 | 0.100 |
Why?
|
Oxygen Consumption | 7 | 1992 | 241 | 0.100 |
Why?
|
Blood Component Transfusion | 1 | 2011 | 13 | 0.100 |
Why?
|
Thrombelastography | 1 | 2011 | 47 | 0.100 |
Why?
|
Antibodies | 1 | 2013 | 354 | 0.100 |
Why?
|
Safety | 2 | 2010 | 151 | 0.090 |
Why?
|
Thromboplastin | 1 | 2010 | 7 | 0.090 |
Why?
|
Protein C Deficiency | 1 | 2010 | 4 | 0.090 |
Why?
|
Nitriles | 1 | 1991 | 160 | 0.090 |
Why?
|
Endotoxemia | 1 | 2010 | 18 | 0.090 |
Why?
|
Serotonin Receptor Agonists | 1 | 2010 | 15 | 0.090 |
Why?
|
Imidazoles | 1 | 1991 | 151 | 0.090 |
Why?
|
Blood Coagulation Disorders | 1 | 2011 | 65 | 0.090 |
Why?
|
Blood Proteins | 3 | 1978 | 145 | 0.090 |
Why?
|
Chronic Disease | 1 | 2013 | 948 | 0.090 |
Why?
|
Remission Induction | 5 | 2018 | 734 | 0.090 |
Why?
|
Data Collection | 2 | 2001 | 374 | 0.090 |
Why?
|
Hemorrhage | 1 | 2011 | 276 | 0.090 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2010 | 155 | 0.090 |
Why?
|
Body Weight | 2 | 2009 | 452 | 0.080 |
Why?
|
Adolescent | 8 | 2021 | 9141 | 0.080 |
Why?
|
Lipopolysaccharides | 1 | 2010 | 292 | 0.080 |
Why?
|
Postoperative Nausea and Vomiting | 1 | 2008 | 17 | 0.080 |
Why?
|
Patents as Topic | 1 | 2008 | 12 | 0.080 |
Why?
|
Contraindications | 1 | 2008 | 71 | 0.080 |
Why?
|
Fibromyalgia | 1 | 2008 | 14 | 0.080 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2008 | 105 | 0.080 |
Why?
|
Placebos | 1 | 2007 | 213 | 0.070 |
Why?
|
Structure-Activity Relationship | 1 | 2008 | 411 | 0.070 |
Why?
|
Anemia, Aplastic | 2 | 1984 | 32 | 0.070 |
Why?
|
Anxiety Disorders | 1 | 2008 | 151 | 0.070 |
Why?
|
Child | 2 | 2017 | 7081 | 0.070 |
Why?
|
Urinary Bladder, Overactive | 1 | 2008 | 90 | 0.070 |
Why?
|
Neuropharmacology | 1 | 2006 | 2 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2018 | 3653 | 0.070 |
Why?
|
Oxygen | 5 | 1978 | 744 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 1 | 2019 | 3436 | 0.070 |
Why?
|
Lung Neoplasms | 5 | 2009 | 2335 | 0.070 |
Why?
|
Carbon Dioxide | 5 | 1992 | 202 | 0.070 |
Why?
|
Depressive Disorder, Major | 1 | 2008 | 165 | 0.070 |
Why?
|
Cathepsin E | 1 | 2005 | 2 | 0.070 |
Why?
|
Vagus Nerve | 1 | 2006 | 49 | 0.070 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2007 | 479 | 0.070 |
Why?
|
Forecasting | 1 | 2006 | 305 | 0.060 |
Why?
|
Hypothermia | 1 | 1984 | 26 | 0.060 |
Why?
|
Fadrozole | 2 | 1996 | 2 | 0.060 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2004 | 39 | 0.060 |
Why?
|
Arterioles | 4 | 1981 | 23 | 0.060 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2005 | 138 | 0.060 |
Why?
|
Carcinogens | 1 | 2004 | 110 | 0.060 |
Why?
|
Arteries | 3 | 1981 | 180 | 0.060 |
Why?
|
Gastrointestinal Tract | 1 | 2006 | 190 | 0.060 |
Why?
|
Ambulatory Care | 1 | 2005 | 186 | 0.060 |
Why?
|
Pneumatosis Cystoides Intestinalis | 1 | 1983 | 6 | 0.060 |
Why?
|
Adenoma | 1 | 2005 | 243 | 0.060 |
Why?
|
Diffusion | 5 | 1978 | 93 | 0.060 |
Why?
|
Heat Exhaustion | 1 | 1983 | 1 | 0.060 |
Why?
|
Dopamine Antagonists | 1 | 2003 | 35 | 0.060 |
Why?
|
Tuberculosis, Pulmonary | 1 | 1983 | 58 | 0.060 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 1983 | 11 | 0.060 |
Why?
|
Sex Factors | 1 | 2006 | 1063 | 0.060 |
Why?
|
Leukemia, Lymphoid | 1 | 1983 | 72 | 0.050 |
Why?
|
Camptothecin | 1 | 2004 | 191 | 0.050 |
Why?
|
Infection Control | 1 | 1984 | 120 | 0.050 |
Why?
|
Pia Mater | 2 | 1979 | 5 | 0.050 |
Why?
|
Network Meta-Analysis | 1 | 2022 | 7 | 0.050 |
Why?
|
Carcinoma | 1 | 2005 | 441 | 0.050 |
Why?
|
Kidney Diseases, Cystic | 1 | 1981 | 21 | 0.050 |
Why?
|
Age Factors | 1 | 2006 | 1860 | 0.050 |
Why?
|
Lorazepam | 2 | 1993 | 14 | 0.050 |
Why?
|
Diphenhydramine | 2 | 1993 | 17 | 0.050 |
Why?
|
Young Adult | 3 | 2021 | 6193 | 0.050 |
Why?
|
School Admission Criteria | 1 | 2001 | 23 | 0.050 |
Why?
|
Prognosis | 3 | 2018 | 3749 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2004 | 645 | 0.050 |
Why?
|
Bone Marrow | 1 | 1983 | 444 | 0.050 |
Why?
|
Surgical Procedures, Operative | 1 | 2003 | 205 | 0.050 |
Why?
|
Survival Rate | 2 | 2018 | 1881 | 0.050 |
Why?
|
Schools, Medical | 1 | 2001 | 134 | 0.050 |
Why?
|
Cerebrovascular Circulation | 2 | 1978 | 222 | 0.040 |
Why?
|
Brain | 3 | 2006 | 2261 | 0.040 |
Why?
|
Blotting, Western | 2 | 2013 | 797 | 0.040 |
Why?
|
Fluorocarbons | 2 | 1978 | 72 | 0.040 |
Why?
|
Headache | 2 | 1997 | 72 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2019 | 207 | 0.040 |
Why?
|
Geriatric Assessment | 1 | 2019 | 182 | 0.040 |
Why?
|
Odds Ratio | 1 | 2019 | 685 | 0.040 |
Why?
|
Pancreas | 1 | 2019 | 242 | 0.040 |
Why?
|
Transplantation, Homologous | 1 | 1999 | 1001 | 0.040 |
Why?
|
Bronchi | 1 | 1978 | 229 | 0.040 |
Why?
|
Ethics, Medical | 1 | 1999 | 308 | 0.040 |
Why?
|
Skull | 1 | 1978 | 251 | 0.040 |
Why?
|
Emetics | 1 | 2016 | 4 | 0.040 |
Why?
|
Estrogen Antagonists | 1 | 1996 | 48 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 1996 | 41 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2019 | 771 | 0.030 |
Why?
|
Living Donors | 1 | 1999 | 344 | 0.030 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 1983 | 782 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2019 | 450 | 0.030 |
Why?
|
Referral and Consultation | 1 | 2019 | 342 | 0.030 |
Why?
|
Dyssomnias | 1 | 2015 | 7 | 0.030 |
Why?
|
Retreatment | 1 | 2016 | 108 | 0.030 |
Why?
|
Kidney Neoplasms | 1 | 1981 | 631 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 1999 | 418 | 0.030 |
Why?
|
Capillaries | 2 | 1974 | 90 | 0.030 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1996 | 156 | 0.030 |
Why?
|
Genes, APC | 2 | 2005 | 26 | 0.030 |
Why?
|
Risk | 1 | 2016 | 660 | 0.030 |
Why?
|
Fatigue | 1 | 2015 | 178 | 0.030 |
Why?
|
Cats | 6 | 1981 | 305 | 0.030 |
Why?
|
Diphosphonates | 1 | 1994 | 36 | 0.030 |
Why?
|
Hypercalcemia | 1 | 1994 | 60 | 0.030 |
Why?
|
Sleep Wake Disorders | 1 | 2015 | 116 | 0.030 |
Why?
|
Aging | 1 | 2019 | 710 | 0.030 |
Why?
|
Constipation | 1 | 1994 | 63 | 0.030 |
Why?
|
Salvage Therapy | 1 | 1995 | 235 | 0.030 |
Why?
|
Diarrhea | 1 | 1994 | 182 | 0.030 |
Why?
|
Buffers | 1 | 2013 | 26 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2014 | 133 | 0.030 |
Why?
|
Biotin | 1 | 2013 | 45 | 0.030 |
Why?
|
Time Factors | 6 | 2004 | 5309 | 0.030 |
Why?
|
Receptors, Fc | 1 | 2013 | 32 | 0.030 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 77 | 0.030 |
Why?
|
Molecular Docking Simulation | 1 | 2013 | 46 | 0.030 |
Why?
|
Nicotine | 1 | 1974 | 199 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 1993 | 155 | 0.030 |
Why?
|
Mice, Knockout | 2 | 2010 | 1987 | 0.030 |
Why?
|
Rituximab | 1 | 2013 | 119 | 0.030 |
Why?
|
Mass Spectrometry | 1 | 2013 | 193 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2019 | 2744 | 0.030 |
Why?
|
Thermodynamics | 1 | 2013 | 309 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 379 | 0.030 |
Why?
|
Kinetics | 2 | 1992 | 1528 | 0.030 |
Why?
|
Antigens | 1 | 2013 | 229 | 0.030 |
Why?
|
Oligopeptides | 1 | 2013 | 191 | 0.030 |
Why?
|
Ligands | 1 | 2013 | 440 | 0.030 |
Why?
|
Estrone | 1 | 1991 | 10 | 0.020 |
Why?
|
Hydroxyprogesterones | 1 | 1991 | 22 | 0.020 |
Why?
|
Androstenedione | 1 | 1991 | 29 | 0.020 |
Why?
|
Multiple Trauma | 1 | 2011 | 31 | 0.020 |
Why?
|
17-alpha-Hydroxyprogesterone | 1 | 1991 | 31 | 0.020 |
Why?
|
Aldosterone | 1 | 1991 | 56 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2013 | 691 | 0.020 |
Why?
|
Leukemia | 2 | 1983 | 321 | 0.020 |
Why?
|
Paclitaxel | 1 | 2013 | 477 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 1 | 1991 | 131 | 0.020 |
Why?
|
Menopause | 1 | 1991 | 76 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2013 | 466 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2010 | 3198 | 0.020 |
Why?
|
Thrombin | 1 | 2010 | 61 | 0.020 |
Why?
|
Disease Progression | 2 | 2005 | 1489 | 0.020 |
Why?
|
Estradiol | 1 | 1991 | 251 | 0.020 |
Why?
|
Radiography | 2 | 1983 | 806 | 0.020 |
Why?
|
Binding Sites | 1 | 2013 | 1113 | 0.020 |
Why?
|
Hydrocortisone | 1 | 1991 | 303 | 0.020 |
Why?
|
Glucose | 1 | 1992 | 630 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 2062 | 0.020 |
Why?
|
Protein Binding | 1 | 2013 | 1484 | 0.020 |
Why?
|
Mice | 3 | 2010 | 11700 | 0.020 |
Why?
|
Random Allocation | 1 | 1989 | 329 | 0.020 |
Why?
|
Blood Viscosity | 1 | 1968 | 16 | 0.020 |
Why?
|
Carcinoma, Small Cell | 1 | 1989 | 133 | 0.020 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 3029 | 0.020 |
Why?
|
Erythrocytes | 2 | 1983 | 254 | 0.020 |
Why?
|
Thymus Hormones | 1 | 1987 | 2 | 0.020 |
Why?
|
Thymopoietins | 1 | 1987 | 7 | 0.020 |
Why?
|
Proteins | 1 | 1993 | 786 | 0.020 |
Why?
|
Lung | 1 | 1974 | 1243 | 0.020 |
Why?
|
Leukocyte Count | 2 | 1987 | 222 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2010 | 1570 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 1 | 1993 | 1094 | 0.020 |
Why?
|
Graft vs Host Disease | 2 | 1987 | 358 | 0.020 |
Why?
|
Hydrogen-Ion Concentration | 2 | 1978 | 499 | 0.020 |
Why?
|
Intestinal Diseases | 1 | 2005 | 79 | 0.020 |
Why?
|
Lymphocytes | 2 | 1987 | 470 | 0.020 |
Why?
|
Peptide Fragments | 1 | 1987 | 460 | 0.020 |
Why?
|
Neoplasm Metastasis | 2 | 2002 | 1095 | 0.020 |
Why?
|
Ranolazine | 1 | 2004 | 4 | 0.020 |
Why?
|
Acetanilides | 1 | 2004 | 6 | 0.020 |
Why?
|
Body Temperature Regulation | 1 | 1984 | 56 | 0.020 |
Why?
|
Environment, Controlled | 1 | 1984 | 8 | 0.020 |
Why?
|
Injections, Intraperitoneal | 1 | 2004 | 101 | 0.010 |
Why?
|
Granulocytes | 1 | 1984 | 38 | 0.010 |
Why?
|
Tuberculoma | 1 | 1983 | 2 | 0.010 |
Why?
|
Mycobacterium Infections, Nontuberculous | 1 | 1983 | 26 | 0.010 |
Why?
|
Organoplatinum Compounds | 1 | 2004 | 96 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 891 | 0.010 |
Why?
|
Mood Disorders | 1 | 2004 | 81 | 0.010 |
Why?
|
Spherocytes | 1 | 1983 | 1 | 0.010 |
Why?
|
Erythrocyte Count | 1 | 1983 | 22 | 0.010 |
Why?
|
Blood Cell Count | 1 | 1983 | 79 | 0.010 |
Why?
|
Rhenium | 1 | 1983 | 3 | 0.010 |
Why?
|
Technetium | 1 | 1983 | 29 | 0.010 |
Why?
|
Blood Transfusion | 1 | 1984 | 164 | 0.010 |
Why?
|
Sulfur | 1 | 1983 | 29 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2004 | 272 | 0.010 |
Why?
|
Bone Marrow Examination | 1 | 1983 | 47 | 0.010 |
Why?
|
Pulmonary Fibrosis | 1 | 1984 | 129 | 0.010 |
Why?
|
Radionuclide Imaging | 1 | 1983 | 221 | 0.010 |
Why?
|
Necrosis | 1 | 1983 | 210 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2004 | 575 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 1983 | 235 | 0.010 |
Why?
|
Gated Blood-Pool Imaging | 1 | 2002 | 8 | 0.010 |
Why?
|
Cerebrospinal Fluid | 2 | 1978 | 31 | 0.010 |
Why?
|
Liposomes | 1 | 2002 | 93 | 0.010 |
Why?
|
Creatinine | 2 | 1993 | 295 | 0.010 |
Why?
|
Neutrophils | 1 | 1983 | 308 | 0.010 |
Why?
|
Renal Artery | 1 | 1981 | 52 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2005 | 1790 | 0.010 |
Why?
|
Critical Care | 1 | 1984 | 377 | 0.010 |
Why?
|
Weight Loss | 2 | 1993 | 225 | 0.010 |
Why?
|
Alleles | 1 | 2004 | 1131 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 1110 | 0.010 |
Why?
|
Muscle, Smooth, Vascular | 1 | 1981 | 242 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2002 | 858 | 0.010 |
Why?
|
Brain Concussion | 1 | 1980 | 63 | 0.010 |
Why?
|
Endothelium | 1 | 1979 | 58 | 0.010 |
Why?
|
Solutions | 1 | 1978 | 85 | 0.010 |
Why?
|
Cerebral Arteries | 1 | 1978 | 74 | 0.010 |
Why?
|
Survival Analysis | 1 | 2002 | 1542 | 0.010 |
Why?
|
Graft Rejection | 1 | 1984 | 1083 | 0.010 |
Why?
|
Ventricular Function, Left | 1 | 2002 | 602 | 0.010 |
Why?
|
Partial Pressure | 1 | 1977 | 50 | 0.010 |
Why?
|
Blood Pressure | 2 | 1980 | 891 | 0.010 |
Why?
|
Premedication | 1 | 1997 | 57 | 0.010 |
Why?
|
Muscle, Smooth | 1 | 1979 | 354 | 0.010 |
Why?
|
Plasma Substitutes | 1 | 1977 | 9 | 0.010 |
Why?
|
Hydrocarbons, Fluorinated | 1 | 1977 | 14 | 0.010 |
Why?
|
Child, Preschool | 1 | 1984 | 3671 | 0.010 |
Why?
|
Cohort Studies | 1 | 2004 | 2833 | 0.010 |
Why?
|
Solubility | 1 | 1977 | 178 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 1998 | 266 | 0.010 |
Why?
|
In Vitro Techniques | 1 | 1978 | 995 | 0.010 |
Why?
|
Respiration | 1 | 1978 | 266 | 0.010 |
Why?
|
Methotrexate | 1 | 1997 | 250 | 0.010 |
Why?
|
Postmenopause | 1 | 1996 | 99 | 0.010 |
Why?
|
Hypertension | 1 | 1981 | 733 | 0.010 |
Why?
|
Acute Disease | 1 | 1997 | 838 | 0.010 |
Why?
|
Chemistry | 1 | 1974 | 54 | 0.010 |
Why?
|
Plants, Toxic | 1 | 1974 | 26 | 0.010 |
Why?
|
Rats | 2 | 1978 | 4034 | 0.010 |
Why?
|
Sodium Chloride | 1 | 1994 | 87 | 0.010 |
Why?
|
gamma-Globulins | 1 | 1974 | 16 | 0.010 |
Why?
|
Alpha-Globulins | 1 | 1974 | 11 | 0.010 |
Why?
|
Chromatography, Gas | 1 | 1974 | 28 | 0.010 |
Why?
|
Membranes | 1 | 1974 | 36 | 0.010 |
Why?
|
Pulmonary Diffusing Capacity | 1 | 1974 | 24 | 0.010 |
Why?
|
Lipoproteins, HDL | 1 | 1974 | 97 | 0.010 |
Why?
|
Serum Albumin | 1 | 1974 | 128 | 0.010 |
Why?
|
Calorimetry | 1 | 1993 | 15 | 0.010 |
Why?
|
Blood Urea Nitrogen | 1 | 1993 | 33 | 0.010 |
Why?
|
Lipoproteins | 1 | 1974 | 136 | 0.010 |
Why?
|
Glycine | 1 | 1993 | 94 | 0.010 |
Why?
|
Hypoxia | 1 | 1978 | 650 | 0.010 |
Why?
|
Calorimetry, Indirect | 1 | 1992 | 15 | 0.010 |
Why?
|
Chlorides | 1 | 1993 | 103 | 0.010 |
Why?
|
Heart Failure | 1 | 2002 | 1171 | 0.010 |
Why?
|
Nutritional Status | 1 | 1992 | 84 | 0.010 |
Why?
|
Potassium | 1 | 1993 | 253 | 0.010 |
Why?
|
Sodium | 1 | 1993 | 331 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 1992 | 382 | 0.010 |
Why?
|
Biological Transport | 1 | 1971 | 399 | 0.010 |
Why?
|
Cell Membrane | 1 | 1974 | 669 | 0.010 |
Why?
|
Energy Metabolism | 1 | 1992 | 278 | 0.010 |
Why?
|
Calcium | 1 | 1994 | 1170 | 0.010 |
Why?
|
Body Mass Index | 1 | 1993 | 768 | 0.010 |
Why?
|
Microcirculation | 2 | 1980 | 106 | 0.010 |
Why?
|
Blood Glucose | 1 | 1992 | 840 | 0.000 |
Why?
|
Vasodilation | 2 | 1978 | 94 | 0.000 |
Why?
|
Blood Flow Velocity | 1 | 1968 | 199 | 0.000 |
Why?
|
Thymopentin | 1 | 1987 | 2 | 0.000 |
Why?
|
Hypersensitivity, Delayed | 1 | 1987 | 25 | 0.000 |
Why?
|
Antibody Formation | 1 | 1987 | 171 | 0.000 |
Why?
|
Graft Survival | 1 | 1987 | 912 | 0.000 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1981 | 140 | 0.000 |
Why?
|
Microscopy, Electron | 1 | 1981 | 508 | 0.000 |
Why?
|
Platelet Aggregation | 1 | 1980 | 44 | 0.000 |
Why?
|
Hypotension | 1 | 1980 | 70 | 0.000 |
Why?
|
Pentylenetetrazole | 1 | 1978 | 2 | 0.000 |
Why?
|
Vasoconstriction | 1 | 1978 | 92 | 0.000 |
Why?
|
Regional Blood Flow | 1 | 1978 | 198 | 0.000 |
Why?
|
Homeostasis | 1 | 1980 | 408 | 0.000 |
Why?
|
Emulsions | 1 | 1977 | 19 | 0.000 |
Why?
|
Seizures | 1 | 1978 | 302 | 0.000 |
Why?
|
Cerebral Cortex | 1 | 1978 | 588 | 0.000 |
Why?
|